Last Updated: July 2026
Published by: oncosolution — a specialist oncology medicine supplier serving patients, pharmacies, and distributors worldwide.
Medical Review: Reviewed by Dr. Rakib Uddin Ahmed, MBBS, MD (Hematology)
Content Basis: This article is based on official prescribing information, product monographs, and regulatory product documentation from NMRA and DGDA (Directorate General of Drug Administration, Bangladesh).
Sources: demo.bioxenpmc.com, tagrix.net, accessdata.fda.gov, accessdata.fda.gov, medex.com.bd, drugs.com, fda.gov
Key Takeaways
- Osimertinib is a third-generation EGFR tyrosine kinase inhibitor approved for adult patients aged 18 years and older with metastatic EGFR T790M mutation-positive NSCLC who have progressed on prior EGFR TKI therapy, as well as for first-line treatment of EGFR-mutated NSCLC.
- Confirmation of the T790M resistance mutation in tumor specimens is a mandatory prerequisite before initiating osimertinib treatment in the T790M-positive setting.
- We export six DDA-authorized, Bangladeshi-manufactured osimertinib brands to Sri Lanka — Osimatab, Osikin, Tagrix, Osinib, Osicent, and Osimert — all available in both 40 mg and 80 mg tablet strengths.
- Tagrix holds the distinction of being the first global generic preparation of osimertinib to receive approval in Bangladesh, reflecting the strength of Bangladesh’s oncology manufacturing base.
- Known serious adverse effects include interstitial lung disease (ILD), pneumonitis, and QTc interval prolongation, all of which require clinical monitoring and prompt evaluation if symptoms arise.
- Sri Lankan importers must verify product registration and import requirements with the National Medicines Regulatory Authority (NMRA) prior to procurement; we can provide supporting export documentation to assist with compliance.
What Is Osimertinib and What Is It Used For?
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) indicated for the treatment of non-small cell lung cancer (NSCLC) in adult patients. It carries two distinct approved indications that address different stages of disease management.
The primary indication is the treatment of metastatic EGFR T790M mutation-positive NSCLC in adult patients aged 18 years and older who have progressed on or after prior EGFR TKI therapy. In this setting, The T790M resistance mutation — which commonly develops following treatment with first- or second-generation EGFR TKIs — must be confirmed via an FDA-approved test before treatment is initiated; confirmation may be achieved through either tumor tissue specimens or plasma-based (liquid biopsy) testing, with tissue testing recommended if plasma results are negative or inconclusive. This confirmation step is a mandatory prerequisite, not a clinical recommendation.
The second approved indication is first-line treatment of EGFR-mutated NSCLC, positioning osimertinib as an option earlier in the treatment pathway for eligible patients with activating EGFR mutations.
As a kinase inhibitor targeting the EGFR pathway, osimertinib represents a significant advance in precision oncology for lung cancer. For B2B procurement professionals and healthcare institutions in Sri Lanka sourcing this therapy, understanding both indications is essential for appropriate product selection and regulatory alignment.
How Osimertinib Works: Mechanism of Action
Osimertinib exerts its anticancer effect through selective inhibition of specific EGFR mutations that drive tumor growth and treatment resistance in NSCLC. Its mechanism distinguishes it from earlier-generation EGFR TKIs in two important ways.
First, osimertinib targets the activating EGFR mutations — specifically exon 19 deletions and exon 21 substitutions — that are responsible for initiating malignant cell proliferation in EGFR-mutated NSCLC. These mutations are the same targets addressed by first- and second-generation EGFR TKIs.
Second, and critically, osimertinib also inhibits the T790M resistance mutation. The T790M substitution in EGFR exon 20 is the most common mechanism by which tumors develop resistance to earlier-generation TKIs. By targeting both the activating mutations and this acquired resistance mutation within a single agent, osimertinib overcomes a major limitation of prior EGFR-directed therapies.
Clinical Insight: This dual-targeting capability is the defining pharmacological feature of third-generation EGFR TKIs and explains the clinical rationale for using osimertinib in patients who have progressed on prior EGFR TKI treatment. The result is continued EGFR pathway suppression even in the presence of T790M-mediated resistance.
Available Brands of Osimertinib We Supply to Sri Lanka
We export the following six Bangladeshi-manufactured osimertinib brands to Sri Lanka, each produced by an established pharmaceutical manufacturer operating under Bangladesh’s Directorate of Drug Administration (DDA) authorization:
- Osimatab (Eskayef Pharmaceuticals Ltd.) — available in 40 mg and 80 mg tablet strengths.
- Osikin (Ziska Pharmaceuticals Ltd.) — available in 40 mg and 80 mg tablet strengths.
- Tagrix (Beacon Pharmaceuticals Ltd.) — available in 40 mg and 80 mg tablet strengths. Tagrix holds the distinction of being the first global generic preparation of osimertinib to receive approval in Bangladesh.
- Osinib (Drug International Ltd.) — available in 40 mg and 80 mg tablet strengths.
- Osicent (Incepta Pharmaceuticals Ltd.) — available in 40 mg and 80 mg tablet strengths.
- Osimert (Everest Pharmaceutical Ltd.) — available in 40 mg and 80 mg tablet strengths. For further clinical and market context on this brand, see our detailed Osimert 80 mg product review.
All six brands are manufactured in Bangladesh and exported directly to Sri Lanka through our B2B supply channel. Both the 40 mg and 80 mg tablet formulations are available across the portfolio, providing flexibility for procurement based on clinical requirements.
For procurement inquiries: Pharmacies, hospitals, and distributors in Sri Lanka are encouraged to contact us directly for current product availability, pack size options, and pricing information.
Regulatory Status: FDA Approval and Bangladesh Authorization
Osimertinib received approval from the U.S. Food and Drug Administration (FDA) in through the accelerated approval pathway. This regulatory mechanism is designed to expedite access to therapies that address serious conditions and demonstrate a meaningful advantage over available treatments. Under accelerated approval, continued authorization is contingent on post-marketing verification of clinical benefit — a standard requirement that reflects the FDA’s commitment to ongoing evidence generation for novel oncology agents.
Regulatory Context: In Bangladesh, osimertinib generics are approved by the Directorate of Drug Administration (DDA), Ministry of Health and Family Welfare. The DDA authorization covers the six brands we supply — Osimatab, Osikin, Tagrix, Osinib, Osicent, and Osimert — confirming their regulatory standing for manufacture and export.
The accelerated approval framework is relevant for procurement professionals to understand: it confirms that the clinical evidence base supporting osimertinib was sufficiently robust to justify early access, while acknowledging that confirmatory trial data continues to be evaluated. For B2B buyers in Sri Lanka, both the FDA approval history and the DDA authorization of Bangladeshi generics provide a credible regulatory foundation for procurement decisions.
Importing Osimertinib into Sri Lanka: NMRA Guidance for Buyers
All pharmaceutical imports into Sri Lanka are regulated by the National Medicines Regulatory Authority (NMRA), accessible at nmra.gov.lk. The NMRA is the statutory body responsible for evaluating, registering, and monitoring medicinal products entering the Sri Lankan market, and compliance with its requirements is mandatory for all importers.
⚠️ Compliance Requirement: B2B buyers — including pharmacies, hospital procurement departments, and wholesale distributors — should verify that any osimertinib product intended for import holds valid registration or authorization under current NMRA guidelines before completing a procurement transaction. Product registration status, required documentation, and import permit procedures are subject to NMRA review and may vary depending on the specific brand and manufacturer.
As a Bangladeshi pharmaceutical exporter, we are experienced in supporting international buyers with the documentation typically required for cross-border pharmaceutical transactions. We can provide relevant product documentation — including certificates of analysis, manufacturer authorization letters, and regulatory dossier support — to assist Sri Lankan buyers in meeting their import compliance obligations.
We strongly advise all procurement professionals to consult directly with the NMRA or a qualified regulatory affairs specialist in Sri Lanka to confirm the current registration status and import requirements applicable to specific osimertinib brands prior to placing orders.
Side Effects and Safety Considerations
⚕️ Healthcare Professional Guidance Required: The following safety information is provided for informational context only. All clinical safety decisions must be managed by qualified healthcare professionals in accordance with the official prescribing information.
Common side effects associated with osimertinib include: diarrhea, rash, leukopenia, thrombocytopenia, neutropenia, lymphopenia, stomatitis, nail toxicity, dry skin, eyelid pruritus, and increased blood creatinine. These adverse effects vary in frequency and severity across individual patients and require clinical monitoring throughout the course of treatment.
Serious adverse effects include interstitial lung disease (ILD), pneumonitis, and QTc interval prolongation. ILD and pneumonitis can be life-threatening and require prompt clinical evaluation if respiratory symptoms develop. QTc prolongation necessitates cardiac monitoring, particularly in patients with pre-existing risk factors or those receiving concomitant QT-prolonging agents.
Drug interactions: Osimertinib is metabolized via the CYP3A4 pathway. Prescribers and clinical pharmacists should evaluate potential interactions with CYP3A4 inducers or inhibitors when reviewing a patient’s full medication profile.
Lactation: Risk data is available regarding osimertinib use during breastfeeding. Healthcare providers and patients should refer to the complete prescribing information for full lactation guidance before making clinical decisions.
Dosage Forms and Administration Overview
Osimertinib is available in two oral tablet strengths: 40 mg and 80 mg. Both formulations are supplied as film-coated tablets intended for oral administration.
The tablets may be taken with or without food, offering flexibility for patient adherence. If a dose is missed, it should not be made up — patients should resume their regular schedule with the next scheduled dose as directed by their treating physician.
Prescriber Determination: Specific dosing regimens, including the appropriate tablet strength and any dose modifications, are determined solely by the treating physician based on the patient’s indication, clinical status, and response to therapy. All dosing decisions should be made in accordance with the official prescribing information.
Procurement professionals should note that both the 40 mg and 80 mg tablet strengths are available across the Bangladeshi brands we export to Sri Lanka, supporting clinical flexibility at the institutional level.
Why Source Osimertinib from a Bangladeshi Supplier?
Bangladesh has established itself as a credible source of high-quality generic oncology medicines, and osimertinib is a prime example of this capability. Six distinct manufacturers — Eskayef Pharmaceuticals, Ziska Pharmaceuticals, Beacon Pharmaceuticals, Drug International, Incepta Pharmaceuticals, and Everest Pharmaceutical — have each received DDA authorization for their respective osimertinib products, reflecting the depth of Bangladesh’s pharmaceutical manufacturing base in this therapeutic category.
Sourcing Advantages:
- Multiple DDA-approved manufacturers providing supply chain redundancy
- Both 40 mg and 80 mg strengths available across all brands
- Documented regulatory standing with Bangladesh DDA authorization
- Established B2B export channel with documentation support
- Cost-effective generic alternatives to originator products
For Sri Lankan healthcare institutions and distributors seeking a reliable osimertinib 80 mg supplier, sourcing from Bangladesh offers access to multiple DDA-approved generic brands with documented regulatory standing. The availability of both 40 mg and 80 mg tablet strengths across the portfolio ensures that procurement can be aligned with clinical requirements at the institutional level.
Osimertinib was originally introduced to the global oncology market under the originator brand Tagrisso, establishing the clinical benchmark for third-generation EGFR inhibition in NSCLC. The Bangladeshi generic brands we supply provide procurement professionals in Sri Lanka with access to this important therapeutic class through a well-established B2B export channel, supported by appropriate manufacturer documentation.
Our export operations are structured to support the documentation and logistical requirements of international pharmaceutical procurement, making us a practical sourcing partner for Sri Lanka’s healthcare supply chain.
How to Inquire About Osimertinib Supply for Sri Lanka
Pharmacies, hospitals, wholesalers, and distributors in Sri Lanka are invited to contact us directly to inquire about osimertinib product availability. We supply both 40 mg and 80 mg tablet pack sizes across our portfolio of Bangladeshi-manufactured brands.
Ready to Source Osimertinib?
Contact our pharmaceutical export team for product availability, specifications, and documentation support.
We provide: Certificates of analysis • Manufacturer authorization • Regulatory dossier support • Competitive B2B pricing
To request product availability information, documentation, or pricing, please reach out through our contact channels. Our team is available to assist B2B procurement professionals with sourcing inquiries, product specifications, and export documentation support tailored to Sri Lanka’s import requirements.
Contact us today to discuss your osimertinib supply requirements and receive a prompt response from our pharmaceutical export team.
Frequently Asked Questions
What is osimertinib used to treat?
Osimertinib is used to treat metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) in adult patients who have progressed on prior EGFR TKI therapy, and it is also approved for the first-line treatment of EGFR-mutated NSCLC. Before starting treatment in the T790M-positive setting, the mutation must be confirmed in tumor specimens. Both indications are for adult patients aged 18 years and older.
What are the common side effects of osimertinib?
Common side effects of osimertinib include diarrhea, rash, nail toxicity, dry skin, stomatitis, leukopenia, and thrombocytopenia, among others. More serious reactions such as interstitial lung disease (ILD), pneumonitis, and QTc interval prolongation require prompt clinical evaluation if they occur. All side effects should be monitored and managed by a qualified healthcare professional throughout the course of treatment.
Can osimertinib tablets be taken with food?
Yes, osimertinib tablets may be taken with or without food, which offers flexibility for patient adherence. If a dose is missed, it should not be made up — patients should simply resume their regular schedule with the next dose as directed by their treating physician. Specific dosing decisions are always determined by the treating physician based on the patient’s individual clinical situation.
Does osimertinib interact with other medications?
Osimertinib is metabolized via the CYP3A4 pathway, which means it may interact with medications that are CYP3A4 inducers or inhibitors. Prescribers and clinical pharmacists should review a patient’s full medication profile to identify any potential interactions before and during treatment. Patients should always inform their healthcare provider of all medications they are taking.
Which Bangladeshi osimertinib brands do you export to Sri Lanka?
We export six DDA-authorized, Bangladeshi-manufactured osimertinib brands to Sri Lanka: Osimatab, Osikin, Tagrix, Osinib, Osicent, and Osimert. All six brands are available in both 40 mg and 80 mg tablet strengths, providing flexibility to meet varying clinical and institutional procurement requirements. Contact us directly for current availability, pack size options, and export documentation support.
What documentation can you provide to support osimertinib imports into Sri Lanka?
We can provide relevant export documentation including certificates of analysis, manufacturer authorization letters, and regulatory dossier support to assist Sri Lankan buyers in meeting NMRA import compliance obligations. Buyers are strongly advised to verify the current registration status and import requirements for specific brands directly with the NMRA or a qualified regulatory affairs specialist in Sri Lanka before placing orders. Our team is available to assist B2B procurement professionals throughout the sourcing and documentation process.
- 1. www.demo.bioxenpmc.com
- 2. tagrix.net
- 3. www.accessdata.fda.gov
- 4. www.accessdata.fda.gov
- 5. medex.com.bd
- 6. www.drugs.com
- 7. www.fda.gov
Access This Medicine Through oncosolution
We are a specialist oncology medicine supplier delivering to patients, pharmacies, hospitals, and distributors worldwide. Contact us for availability and sourcing support.
We do not publish prices online. All pricing is provided directly by our specialist supply team on request.
Medical Information Notice: This content is for informational purposes only and is based on official pharmaceutical product documentation. It does not constitute medical advice. Patients should consult their doctor or pharmacist before taking any medication.
Regulatory Disclaimer: Sourcing and distribution are subject to regional import regulations, quotas, and verified medical prescriptions where applicable. Pricing and availability are subject to change without notice.
Content Currency: This article was last reviewed and updated in July 2026. Regulatory approval statuses and product availability are subject to change; readers are advised to consult official regulatory databases for the most current information.